Janice Walsh

Now, they can produce different types of toxicities.

And for many of the women who are on these drugs, they will know about it, particularly, let's say, some eye effects.

But in terms of nausea and fatigue, those really debilitating side effects for many of our standard care chemotherapy drugs, where they affect both our abnormal cells and normal cells, it has dramatically reduced that.

So many of the women who would have participated in these trials would have talked about, in addition to the fact that they're delighted to hear that they have better survival as a result of these drugs, they have better quality of life.

So I heard this described during the week as a sat-nav, which tracks down the cancer.

Do you think that's an accurate description, that it goes to hunt for the cancer cells?

Well, I think it's just one of these targeted therapies and we're moving towards this personalised care.

So I think within this group, that is correct.

So you mentioned there that not much has changed when it comes to the treatment of ovarian cancer.

Cancer in general, though, is treatments changing very rapidly now because we have had or certainly feels like we've had a number of announcements in recent months.

I think cancer care has been radically changed, Clare, over the last five and 10 years.

As a result of better technologies to be able to interrogate both tumour and circulating cells within the body, we have been able to identify targets

genes that essentially are switched on, switched off and allowed us then to develop drugs that target those.

So I think, you know, for many of us, we came back from Chicago in June.

The largest international cancer conference is part of the American Society of Clinical Oncology.

And every year we're

We go over there to essentially network to try and get clinical trial opportunities for our patients and to talk about new developments that are occurring.

And honestly, the level of groundbreaking research that is emerging at the moment is really unprecedented.

I would say that every four months we have new data coming out in all different cancer types that very often is practice changing.

And I think what's been really encouraging is, you know, I'm a breast cancer specialist.